DRDO has developed an antibody detection kit called ‘DIPCOVAN’. The kit can detect both spike and nucleocapsid (S&N) proteins of SARS-CoV-2 virus with a high sensitivity of 97 per cent and specificity of 99 per cent.
The kit was approved by the Indian Council of Medical Research (ICMR) in April 2021. In May 2021, the product received regulatory approval from the Drugs Controller General of India (DCGI), Central Drugs Standard Control Organisation (CDSCO), Ministry of Health and Family Welfare to manufacture for sale and distribution.
DIPCOVAN is intended for qualitative detection of IgG antibodies in human serum or plasma, targeting SARS-CoV-2 related antigens. It offers a significantly faster turn-around time as it requires just 75 minutes.
The product will be launched in the first week of June 2021.